Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Open Access
- 29 September 2025
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (9) , e0333526
Abstract
Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical Perna canaliculus oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P = 0.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P = 0.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P = 0.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.Keywords
Funding Information
- Pharmalink International Ltd. Central, Hong Kong (NA)
This publication has 36 references indexed in Scilit:
- Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST StudyJournal of Veterinary Internal Medicine, 2008
- Anti-cyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel, Perna canaliculusComparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 2007
- Sildenafil Citrate Therapy In 22 Dogs with Pulmonary HypertensionJournal of Veterinary Internal Medicine, 2007
- Doppler echocardiography–derived evidence of pulmonary arterial hypertension in dogs with degenerative mitral valve disease: 86 cases (2001–2005)Journal of the American Veterinary Medical Association, 2006
- Gas chromatography‐chemical ionization‐mass spectrometric fatty acid analysis of a commercial supercritical carbon dioxide lipid extract from New Zealand green‐lipped mussel (Perna canaliculus)Lipids, 2005
- Evaluation of the six-minute walk test in dogsAmerican Journal of Veterinary Research, 2004
- Allometric Scaling of M-Mode Cardiac Measurements in Normal Adult DogsJournal of Veterinary Internal Medicine, 2004
- LEFT ATRIAL TO AORTIC ROOT INDICES USING TWO‐DIMENSIONAL AND M‐MODE ECHOCARDIOGRAPHY IN CAVALIER KING CHARLES SPANIELS WITH AND WITHOUT LEFT ATRIAL ENLARGEMENTVeterinary Radiology & Ultrasound, 2002
- Clinical Characteristics of 53 Dogs with Doppler-Derived Evidence of Pulmonary Hypertension: 1992–1996Journal of Veterinary Internal Medicine, 1999
- Anti-inflammatory activity of a lipid fraction (lyprinol) from the NZ green-lipped musselInflammopharmacology, 1997